Pharmacogenomics of antipsychotics efficacy for schizophrenia. - Wikidata - awgldk - TriplyDB

Pharmacogenomics of antipsychotics efficacy for schizophrenia.

Pharmacogenomics of antipsychotics efficacy for schizophrenia.

http://www.wikidata.org/entity/Q37832287

about

Pharmacogenetics and outcome with antipsychotic drugs Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes The genetics of cognitive impairment in schizophrenia: a phenomic perspective.Clinical applications of schizophrenia genetics: genetic diagnosis, risk, and counseling in the molecular era Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations.Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.Systems biology, bioinformatics, and biomarkers in neuropsychiatry.Pharmacogenomics can improve antipsychotic treatment in schizophrenia.rs7968606 polymorphism of ANKS1B is associated with improvement in the PANSS general score of schizophrenia caused by amisulpride.

P2860

Q26852807-DC3AEB80-CC72-4D8D-9A7D-97D06D11BBB6 Q28088705-EACE2161-2990-40E0-9AB1-C57B80215BF0 Q35186661-724082C3-E748-4355-8F9A-2BB8945CC5EE Q36380279-6660EC9E-AC5F-4102-A9EE-980EE659A191 Q37344782-6BAA4642-92C0-4364-8F05-2D0BBD4035BE Q38042478-DAEBD155-113A-43FD-BCFD-5DAFB12E6CCA Q38069972-B8027B60-CFC6-43EC-9449-9E0C19958A24 Q38100731-7EC745E2-E024-4953-8DE0-C735A9ECB198 Q38741135-530065F5-9E5A-40AA-9AA5-BF84DB5B3767

P2860

Pharmacogenomics of antipsychotics efficacy for schizophrenia.

http://www.wikidata.org/entity/Q37832287

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pharmacogenomics of antipsychotics efficacy for schizophrenia.

@en

Pharmacogenomics of antipsychotics efficacy for schizophrenia.

@nl

type

label

Pharmacogenomics of antipsychotics efficacy for schizophrenia.

@en

Pharmacogenomics of antipsychotics efficacy for schizophrenia.

@nl

prefLabel

Pharmacogenomics of antipsychotics efficacy for schizophrenia.

@en

Pharmacogenomics of antipsychotics efficacy for schizophrenia.

@nl

P1433

Q37832287-C5405C1C-E18A-427C-8C4F-75D5550B1126

P1476

Q37832287-13097CF2-F371-4D56-8F99-DA15C9E60848

P2093

Q37832287-1CA4123F-978E-4D90-B8DD-01CECD255EE5

Q37832287-4A9CE50A-339D-4AAC-BBC2-301932FDFAED

P2860

Q37832287-028EA582-917B-401A-AA2C-B48F63688688

Q37832287-09A95B1D-2792-4A68-9921-4F297F0573CB

Q37832287-09B8F6A5-B3B4-4938-A7D6-4EC36174B9E2

Q37832287-0C9051EA-340C-4CC8-ACDD-900C0587C4B1

Q37832287-10C769E1-A8FD-4699-B73A-D2916C179065

Q37832287-14F328A9-E73E-4256-8132-AA00812271D1

Q37832287-176FA46B-1CAC-4A4D-9272-379C3E413952

Q37832287-17E201B9-6213-499F-8C83-FDD9264621CE

Q37832287-1A848C7D-B243-4EA6-B054-FBB823F69848

Q37832287-1C778EC8-1FCA-4018-8944-ED9059F7E377

P304

Q37832287-A403A4C3-FC86-4A94-A59E-50FEEC232992

P31

Q37832287-BEB66226-942C-4434-98AB-19FFAE030124

P356

Q37832287-6A4166DB-1C90-4D92-AC83-D1E29EED69D0

P433

Q37832287-7A727239-6F4B-45B3-9318-236BE291F6E8

P478

Q37832287-B428F807-DC78-47DF-9FD5-86309FF09102

P50

Q37832287-68F798AC-67E3-432F-A182-2B5EC6297B12

P577

Q37832287-519FDE06-8D02-485D-B9C7-4262C0C43BB7

P5875

Q37832287-8CA562C9-91CB-466B-8112-49749D014622

P698

Q37832287-839B824B-5920-4D48-AB7E-7E3110A67294

P921

Q37832287-AB34D6F9-AFD3-4E49-BE08-DBC40E2EBEDE

Q37832287-F04BED2F-6996-45E1-ADD6-7F2CE017F74F

P356

J.1440-1819.2010.02168.X

P1433

Psychiatry and Clinical Neurosciences

P1476

Pharmacogenomics of antipsychotics efficacy for schizophrenia.

@en

P2093

Masatoshi Takeda

http://www.w3.org/2001/XMLSchema#string

Ryota Hashimoto

http://www.w3.org/2001/XMLSchema#string

P2860

Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia

CYP2C9 allelic variants: ethnic distribution and functional significance

Making the case for a candidate vulnerability gene in schizophrenia: Convergent evidence for regulator of G-protein signaling 4 (RGS4)

Chronic psychotropic drug treatment causes differential expression of Reelin signaling system in frontal cortex of rats

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene.

The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia.

Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia.

Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects.

Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain.

P304

3-19

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1440-1819.2010.02168.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P50

Ramón Cacabelos

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49784411

http://www.w3.org/2001/XMLSchema#string

P698

21265934

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics